Advertisement

Topics

Methods for Treating or Ameliorating Fibrosis by Inhibiting the Interaction between IL-21 Receptor (IL-21R) and IL-21

20:00 EDT 28 Jul 2009 | NIH

This invention includes methods for treating or ameliorating fibrosis by inhibiting the interaction between IL-21 Receptor (IL-21R) and IL-21 using either anti-IL-21R monoclonal antibodies (or binding fragments of anti-IL-21R mAbs), anti-IL-21 monoclonal antibodies (or binding fragments of anti-IL-21 mAbs) or soluble IL-21R (or binding fragments of IL-21R). It is believed that the TH2 immune response, induced by IL-21, plays a major role in the in the pathogenesis of tissue fibrosis. Antagonism of IL-21R by anti-IL-21R monoclonal antibodies or the sequestration of IL-21 by soluble IL-21R or anti-IL-21 monoclonal antibodies has been demonstrated to reduce TH2 immune responses associated with fibrosis in animal models.

The causes of chronic tissue fibrosis are diverse and the market for a therapeutic that targets fibrosis is large. Fibrosis is associated with diverse causes which include: genetic diseases (such as cystic fibrosis); autoimmune diseases (such as scleroderma); chronic viral infections (such as hepatitis), parasitic infections (such as schistosomiasis); and occupational exposures to causative agents (such as asbestosis). Additionally, many cases of tissue fibrosis are idiopathic.

IC: 
NIAID
NIH Ref. No.: 
E-250-2005-0
TAB No: 
TAB-1996
Applications: 
  • The treatment or amelioration of tissue fibrosis.
Provider Technology ID: 
1996
Updated On: 
May 16, 2018
Provider Classifications: 
Date Published: 
Wednesday, July 29, 2009
Publications: 
Patent Application: 
60/671,374
11/402,885
PCT/US2006/013829
13/030,840
Patent Authority: 
US
US
PCT
US
Patent Number: 
7,910,105
Licensing Contacts: 
Lead Inventor: 
Inventor IC: 
NIAID
LPM FIrst Name: 
James
LPM Last Name: 
Robinson
LPM Address: 
BG 5601FL RM 6D27 MSC 9804 5601 FISHERS LN
LPM City: 
Bethesda
Inv Is lead: 
LPM Zip: 
20892-9804
LPM State: 
MD
LPM Phone: 
301-761-7542
LPM Organization: 
NIH Office of Technology Transfer
DTDT Classification: 
Cancer
Therapeutics
Immunoconjugates
MAb
Immunomodulators and Immunostimulants
DTDT Description: 
Cancer
Cancer - Therapeutics
Cancer - Therapeutics - Immunoconjugates
Cancer - Therapeutics - Immunoconjugates: MAb
Cancer - Therapeutics: Immunomodulators and Immunostimulants
Pat Filing Date: 
2005-04-14
2006-04-13
2006-04-13
2011-02-18
Patent Issue Date: 
2011-03-22
Publication Link: 
https://www.ncbi.nlm.nih.gov/pubmed/16778988
Publication Caption: 
PMID 16778988
Publication Title: 

Pesce J, et al. The IL-21 receptor augments Th2 effector function and alternative macrophage activation.

Additional Patents: 
International rights available.
Disease Area Term: 
Collaboration Sought: 
Yes
Institute or Center: 
E Number Only: 
E-250-2005-0
Inventor First Name: 
Thomas
Inventor Last Name: 
Wynn

Original Article: Methods for Treating or Ameliorating Fibrosis by Inhibiting the Interaction between IL-21 Receptor (IL-21R) and IL-21

NEXT ARTICLE

More From BioPortfolio on "Methods for Treating or Ameliorating Fibrosis by Inhibiting the Interaction between IL-21 Receptor (IL-21R) and IL-21"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...